Medication info

Ibandronate Sodium Injection (Ibandronate Sodium Monohydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Korea Pharma Co., Ltd.
Appearance
A colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, with an attached single-use injection needle.
Packaging
3mL x 1 vial
Approval status
Active

MFDS item code 201702034 · Notified 2017.04.21 · Insurance code 653005911

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is ≤200 µmol/L(2.3mg/dL) or whose creatinine clearance is at least 30ml/min. Use of this medicine is not recommended in patients whose serum creatinine is greater than 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, because clinical experience in these patients is insufficient. Older patients No dose adjustment is necessary.
Child administration
Efficacy and safety have not been studied in children 18 years of age or younger.

Ingredients

Manufacturer
Korea Pharma Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis in postmenopausal women
View approved original text

This medication is used for the treatment of osteoporosis in postmenopausal women. It helps increase bone density and reduce the risk of fractures, aiding in the maintenance of a healthy skeleton. Regular use may effectively prevent complications related to osteoporosis.

How it is given

Adult administration

Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is ≤200 µmol/L(2.3mg/dL) or whose creatinine clearance is at least 30ml/min. Use of this medicine is not recommended in patients whose serum creatinine is greater than 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, because clinical experience in these patients is insufficient. Older patients No dose adjustment is necessary.

Child administration

Efficacy and safety have not been studied in children 18 years of age or younger.

Precautions

This medication must be administered intravenously, and caution is required as administration into arteries or perivascular injection can cause damage to surrounding tissues. It should not be used in patients with an allergy to this drug or its ingredients, or in untreated hypocalcemia. During treatment, gastrointestinal side effects such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, and constipation may occur. Musculoskeletal side effects such as myalgia, arthralgia, and musculoskeletal pain may also arise. Some patients may experience systemic and skin adverse reactions such as flu-like symptoms, fatigue, headache, and rash. This drug can temporarily lower serum calcium levels; therefore, it is necessary to treat metabolic disorders like hypocalcemia before administration and ensure adequate intake of calcium and vitamin D. Patients undergoing dental treatment or with poor oral hygiene are at risk of osteonecrosis of the jaw and should have a dental examination prior to administration. During treatment, excessive dental procedures should be avoided, and if symptoms of osteonecrosis of the jaw appear, medical consultation should be sought immediately. Serious allergic reactions such as external auditory canal osteonecrosis, ocular inflammation, and anaphylaxis have also been reported; immediate medical attention is required if symptoms occur. Long-term use may result in atypical fractures in the femur and other bones, so patients should inform healthcare professionals of any pain in the thigh or groin. This drug has not been confirmed safe for use in pregnant or breastfeeding women, so its use is not recommended. No dosage adjustment is needed for the elderly, but safety and efficacy in children under 18 have not been established. Overdose may affect the kidneys and liver, so renal and hepatic functions should be monitored regularly, and appropriate treatment should be received if necessary. This medication should not be mixed with calcium-containing solutions and must be administered exclusively by intravenous injection. After use, the injection needle and syringe should not be reused and should be disposed of safely.

Side effects

  • Gastritis
  • diarrhea
  • abdominal pain
  • dyspepsia
  • nausea
  • constipation
  • musculoskeletal pain
  • joint pain
  • muscle pain
  • influenza-like illness
Show 65 more
  • fatigue
  • headache
  • rash
  • bone pain
  • frailty
  • injection site reaction
  • phlebitis
  • thrombophlebitis
  • hypersensitivity reaction
  • angioedema
  • facial swelling
  • edema
  • urticaria
  • uveitis
  • episcleritis
  • scleritis
  • anaphylactic reaction
  • shock
  • exacerbation of asthma
  • Stevens-Johnson syndrome
  • erythema multiforme
  • bullous dermatitis
  • atypical pathologic fracture
  • intertrochanteric femoral fracture
  • muscle pain
  • joint pain
  • dyspepsia
  • influenza-like illness
  • musculoskeletal pain
  • headache
  • gastritis
  • nausea
  • fatigue
  • dizziness
  • fever
  • hypothyroidism
  • peripheral motor neuropathy
  • hearing loss
  • dyspnea
  • skin desquamation
  • multiple organ failure
  • death
  • dizziness
  • fracture
  • optic atrophy
  • lower motor neuron lesions
  • tremor
  • unspecified gastrointestinal disorders
  • benign gastrointestinal neoplasm
  • dental pain
  • hyperventilation
  • cough
  • laryngitis
  • vaginitis
  • menopausal symptoms
  • insomnia
  • anxiety
  • tinnitus
  • lipoma
  • ocular hemorrhage
  • heart failure
  • urinary disorders
  • hematuria
  • sensory loss
  • acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air and moisture, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage will help ensure the drug's efficacy is maintained safely.

Appearance and packaging

Appearance

A colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, with an attached single-use injection needle.

Package unit

3mL x 1 vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.